Skip to content

Released Feb 24, 2026, before the open

10-K filed Feb 24, 2026, 55 days after period end · 0001193125-26-065189

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$219.91Mderived+2.0% vs Q4 2024+6.9% vs Q3 2025
Net Income-$2.22MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$156,342,000+5.0%
Operating Incomederived$494,000N/M
Operating Cash Flowderived$27,697,000+16.7%
Free Cash Flowderived$16,820,000+19.6%
Margins · derived
Gross margin71.1%+2.1 pt vs Q4 2024
Operating margin0.2%+5.5 pt vs Q4 2024
Net margin-1.0%+12.5 pt vs Q4 2024

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Revenue$219.91M$215.66M$200.42M$122.23M
Net Income-$2.22M-$29.15M-$22.17M-$7.06M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR